Literature DB >> 23269996

Medical oncologists' perceptions of financial incentives in cancer care.

Jennifer L Malin1, Jane C Weeks, Arnold L Potosky, Mark C Hornbrook, Nancy L Keating.   

Abstract

PURPOSE: The cost of cancer care continues to increase at an unprecedented rate. Concerns have been raised about financial incentives associated with the chemotherapy concession in oncology practices and their impact on treatment recommendations.
METHODS: The objective of this study was to measure the physician-reported effects of prescribing chemotherapy or growth factors or making referrals to other cancer specialists, hospice, or hospital admissions on medical oncologists' income. US medical oncologists involved in the care of a population-based cohort of patients with lung or colorectal cancer from the Cancer Care Outcomes Research and Surveillance (CanCORS) study were surveyed regarding their perceptions of the impact of prescribing practices or referrals on their income.
RESULTS: Although most oncologists reported that their incomes would be unaffected, compared with salaried oncologists, physicians in fee-for-service practice, and those paid a salary with productivity incentives were more likely to report that their income would increase from administering chemotherapy (odds ratios [ORs], 7.05 and 7.52, respectively; both P < .001) or administering growth factors (ORs, 5.60 and 6.03, respectively; both P < .001).
CONCLUSION: A substantial proportion of oncologists who are not paid a fixed salary report that their incomes increase when they administer chemotherapy and growth factors. Further research is needed to understand the impact of these financial incentives on both the quality and cost of care.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269996      PMCID: PMC3565179          DOI: 10.1200/JCO.2012.43.6063

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  23 in total

1.  Concrete options and ideas for increasing value in oncology care: the view from one trench.

Authors:  Thomas J Smith; Bruce E Hillner
Journal:  Oncologist       Date:  2010

2.  Estimated cost savings associated with the transfer of office-administered specialty pharmaceuticals to a specialty pharmacy provider in a Medical Injectable Drug program.

Authors:  Christopher G Baldini; Eric J Culley
Journal:  J Manag Care Pharm       Date:  2011 Jan-Feb

Review 3.  Costs of cancer care: a view from the centers for Medicare and Medicaid services.

Authors:  Peter B Bach
Journal:  J Clin Oncol       Date:  2007-01-10       Impact factor: 44.544

4.  Launching accountable care organizations--the proposed rule for the Medicare Shared Savings Program.

Authors:  Donald M Berwick
Journal:  N Engl J Med       Date:  2011-03-31       Impact factor: 91.245

5.  Oncology services for members of a national managed care company.

Authors:  H Zarkowsky
Journal:  Cancer       Date:  1998-05-15       Impact factor: 6.860

6.  Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.

Authors:  Arnold L Potosky; Jennifer L Malin; Benjamin Kim; Elizabeth A Chrischilles; Solomon B Makgoeng; Nadia Howlader; Jane C Weeks
Journal:  J Natl Cancer Inst       Date:  2011-06-13       Impact factor: 13.506

7.  A population-based assessment of specialty physician involvement in cancer clinical trials.

Authors:  Carrie N Klabunde; Nancy L Keating; Arnold L Potosky; Anita Ambs; Yulei He; Mark C Hornbrook; Patricia A Ganz
Journal:  J Natl Cancer Inst       Date:  2011-02-11       Impact factor: 13.506

8.  An International Health Track Is Associated With Care for Underserved US Populations in Subsequent Clinical Practice.

Authors:  Andrew W Bazemore; Linda M Goldenhar; Christopher J Lindsell; Philip M Diller; Mark K Huntington
Journal:  J Grad Med Educ       Date:  2011-06

9.  Multiple imputation in a large-scale complex survey: a practical guide.

Authors:  Y He; A M Zaslavsky; M B Landrum; D P Harrington; P Catalano
Journal:  Stat Methods Med Res       Date:  2009-08-04       Impact factor: 3.021

10.  Evaluation of trends in the cost of initial cancer treatment.

Authors:  Joan L Warren; K Robin Yabroff; Angela Meekins; Marie Topor; Elizabeth B Lamont; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2008-06-10       Impact factor: 13.506

View more
  10 in total

1.  Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice.

Authors:  Aaron P Mitchell; Alan C Kinlaw; Sharon Peacock-Hinton; Stacie B Dusetzina; Hanna K Sanoff; Jennifer L Lund
Journal:  Oncologist       Date:  2019-10-14

2.  Improving outpatient oncology practice: several steps into a long journey.

Authors:  Rena M Conti; Peter B Bach
Journal:  J Oncol Pract       Date:  2014-10-14       Impact factor: 3.840

3.  Diffusion of Bevacizumab Across Oncology Practices: An Observational Study.

Authors:  Nancy L Keating; Haiden A Huskamp; Deborah Schrag; John M McWilliams; Barbara J McNeil; Bruce E Landon; Michael E Chernew; Sharon-Lise T Normand
Journal:  Med Care       Date:  2018-01       Impact factor: 2.983

4.  Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist.

Authors:  Blase Polite; Rena M Conti; Jeffery C Ward
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

5.  Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy.

Authors:  Nirosha Mahendraratnam; Joel F Farley; Ethan Basch; Amber Proctor; Stephanie B Wheeler; Stacie B Dusetzina
Journal:  Support Care Cancer       Date:  2019-03-26       Impact factor: 3.603

6.  Rationing healthcare: who's responsible?

Authors:  Elizabeth Dzeng; Thomas J Smith
Journal:  Oncology (Williston Park)       Date:  2013-02       Impact factor: 2.990

7.  Perspectives of Japanese oncologists on the health economics of innovative cancer treatments.

Authors:  Tomoyuki Takura; Mikihiro Fujiya; Yasuhiro Shimada; Yutaka Kohgo
Journal:  Int J Clin Oncol       Date:  2015-12-14       Impact factor: 3.402

8.  Patient and oncologist discussions about cancer care costs.

Authors:  Nora B Henrikson; Leah Tuzzio; Elizabeth Trice Loggers; Janice Miyoshi; Diana S M Buist
Journal:  Support Care Cancer       Date:  2013-11-26       Impact factor: 3.603

9.  Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy.

Authors:  Clara N Lee; Matthew H Wetschler; Yuchiao Chang; Jeffrey K Belkora; Beverly Moy; Ann Partridge; Karen R Sepucha
Journal:  BMC Med Inform Decis Mak       Date:  2014-08-20       Impact factor: 2.796

Review 10.  Choosing wisely in oncology: necessity and obstacles.

Authors:  Piercarlo Saletti; Piero Sanna; Luca Gabutti; Michele Ghielmini
Journal:  ESMO Open       Date:  2018-07-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.